Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
On-Q-ity Raises $21M in A Round for Personalized Cancer Testing
|
Ryan McBride |
11/03/09 |
Boston
|
|
Seattle Biotech Needs More Bars, Less University Red Tape, and the Same Daring Attitude, & Other Highlights from Seattle Life Sciences 2029
|
Luke Timmerman |
10/21/09 |
Seattle
|
|
Isis CEO Vows that Cholesterol Drug, Partnered With Genzyme, Will be “Remarkable” Advance
|
Luke Timmerman |
10/21/09 |
San Diego
|
|
Six Tips on How to Spot a Winning Biotech, From Dendreon Co-Founder Chris Henney
|
Luke Timmerman |
10/14/09 |
Seattle
|
|
Public Biotechs’ Finances Foundering, Epizyme Banks $32M, Paratek Cuts Deal with Novartis, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
10/09/09 |
Boston
|
|
Polaris Picks Immuneering, Developer of Personalized Cancer Test, as First Life Sciences Startup in Dog Patch Incubator
|
Luke Timmerman |
10/08/09 |
Boston
|
|
The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten
|
Luke Timmerman |
10/08/09 |
Boston
|
|
DC Matters, But Biotech Can’t Neglect City Hall
|
David Miller |
10/07/09 |
Seattle
|
|
Genzyme Drug Fails to Win FDA Nod
|
Luke Timmerman |
10/06/09 |
Boston
|
|
Former Harvard Official Tapped to Expand Tech Transfer at Brown U.
|
Ryan McBride |
10/01/09 |
Boston
|
|
Genzyme Faces More Setbacks, Humedica Creating a Healthcare “Census,” Pops Back as Alkermes CEO, & More Boston-Area Life Science News
|
Ryan McBride |
09/30/09 |
Boston
|
|
Alkermes’ Ambitious Builder, Richard Pops, Grabs Reins to Re-Ignite Growth Phase
|
Luke Timmerman |
09/28/09 |
Boston
|
|
Genzyme Says Supplies, Sales of Two Enzyme Drugs Will Be Even Lower Than Previously Predicted
|
Wade Roush |
09/23/09 |
Boston
|
|
Biogen Idec Still Pursuing Facet Acquisition, Helicos Gets $10M Reprieve, Seaside Collects $30M for Autism Drug Development, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
09/23/09 |
Boston
|
|
Ascent Therapeutics’ Blood Cancer Drug Could Rival Genzyme’s Mozobil
|
Ryan McBride |
09/16/09 |
Boston
|
|
Acceleron Aims for Anemia Cure, Mascoma to Pump Out Biofuels For Chevron, Genzyme Chief to Head Boston Fed, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
09/16/09 |
Boston
|
|
Pervasis Therapeutics Secures $10M in New Financing
|
Ryan McBride |
09/15/09 |
Boston
|
|
Termeer to Chair Boston Fed Reserve
|
Ryan McBride |
09/15/09 |
Boston
|
|
Arena Prepares to Release Big Obesity Study, Minnow Medical Goes Into ‘Commercialization Mode,’ Metabasis Hires Strategic Adviser, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
09/10/09 |
San Diego
|
|
Ambit Biosciences, In Third Incarnation, Gears Up for Pivotal Study of Leukemia Drug
|
Luke Timmerman |
09/10/09 |
San Diego
|
|
Targeted Genetics Lives On, CellCyte Charged With Fraud, Theraclone Finds HIV Weakness, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
09/10/09 |
Seattle
|
|
Targeted Genetics Survives Brush With Death, Sells Gene Therapy IP to Genzyme for $7M
|
Luke Timmerman |
09/09/09 |
National
|
|
Genzyme’s Woes Piling Up as FDA Panel Says Data on Leukemia Drug are Lacking
|
Luke Timmerman |
09/01/09 |
Boston
|
|
Another Genzyme Rival Advancing
|
Ryan McBride |
09/01/09 |
Boston
|
|
Resolvyx Nails Dry Eye Trial, Gloucester Pulls in $29M, Shire Beefs Up Mass Presence, & Other Boston-Area Life Sciences News
|
Luke Timmerman |
08/26/09 |
Boston
|
|
Genzyme Rival Gets Another FDA Break
|
Luke Timmerman |
08/25/09 |
Boston
|
|
Genzyme Rival Gets FDA Nod
|
Luke Timmerman |
08/17/09 |
Boston
|
|
Biogen Idec Faces Suit From Partner Elan, Genzyme Wins European Approval for Stem-Cell Boosting Drug, Alnylam Teams with Tekmira, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
08/12/09 |
Boston
|
|
Sequenom Maintains Tight Lid on “Mishandled Data” of Key Diagnostic Test
|
Denise Gellene |
08/11/09 |
San Diego
|
|
Genzyme’s Mozobil Gets European Approval
|
Ryan McBride |
08/05/09 |
Boston
|
|
Page 1 of
7 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
